↑ 薬物リストへ　← 戻る

Secukinumab 150 mg (2 injections per dose    (DrugBank: Secukinumab)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
269化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群1

269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群　［臨床試験数：20，薬物数：26（DrugBank：10），標的遺伝子数：12，標的パスウェイ数：90］
Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 20 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04274166
(ClinicalTrials.gov)		January 202112/2/2020Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumThe Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumPyoderma GangrenosumDrug: secukinumab 150 mg (2 injections per doseWake Forest University Health SciencesNovartisNot yet recruiting18 Years75 YearsAll6Phase 2United States